nsclc
As more health authorities approve targeted compounds in a variety of treatment lines, use of this approach is expected only to increase.Gefitinib, an oral tyrosine kinase inhibitor (tki), is approved by Health Canada in the first-line setting of advanced non-small-cell lung carcinoma (nsclc) for tumours that harbour the EGFR gene mutation.
As more health authorities approve targeted compounds in a variety of treatment lines, use of this approach is expected only to increase.Gefitinib, an oral tyrosine kinase inhibitor (tki), is approved by Health Canada in the first-line setting of advanced <span class="disease" id="22787412-2-256-285">non-small-cell lung carcinoma</span> (<span class="disease" id="22787412-2-287-292">nsclc</span>) for tumours that harbour the <span class="gene" id="22787412-2-323-327">EGFR</span> gene mutation.